Advances in cell therapy for solid tumours: European perspective and future directions

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Cell therapy, including CAR-T, TILs, and TCR-T, has transformed cancer treatment, particularly in blood cancers.
• Recent approvals for solid tumors mark a new era, with Europe playing a key role in trials and manufacturing.

Purpose of the Study:

• To examine the latest cell therapy advancements, focusing on the European context and global trends.
• To discuss challenges in Europe, including regulatory hurdles, manufacturing scalability, and access disparities.
• To highlight emerging innovations and future directions for cell therapy integration in oncology.

Main Methods:

• Review of current cell therapy landscape, including CAR-T, TILs, and TCR-T therapies.
• Analysis of European advancements, regulatory frameworks, and manufacturing initiatives.
• Comparison of global trends and emerging innovations like gene-edited and allogeneic cell products.

Main Results:

• Cell therapies demonstrate significant efficacy in hematological malignancies and growing promise in solid tumors.
• Europe is central to cell therapy trials and manufacturing but faces fragmented regulations and access issues.
• Innovations like gene-edited, allogeneic, and iPSC-derived therapies offer potential solutions for scalability and safety.

Conclusions:

• Cell therapies represent a paradigm shift in cancer treatment, with solid tumor applications expanding.
• Addressing European challenges in regulation, cost, and access is crucial for equitable patient benefit.
• Future directions involve integrating advanced cell therapies into mainstream oncology, focusing on innovation and accessibility.